ライフサイエンスコーパス: NYHA

1 NYHA class correlated well with the above parameters of

2 NYHA class improved (IV to II).

3 NYHA functional classification, QOL, and clinical compos

4 NYHA IV subjects required more hemodynamic support, were

5 NYHA status improved by one class in 34% of iloprost ver

6 (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versus III; P=0.19; NYHA I versus II; P=0.55), co

7 primary endpoint were male sex (p = 0.022), NYHA functional class III or IV (p < 0.001), and peak ao

8 NYHA IV (n=111) and NYHA II and III (n=1254) NYHA IV had lower left ventricular ejection fraction; mo

9 NYHA IV; P=0.01; NYHA I versus III; P=0.19; NYHA I versus II; P=0.55), concomitant revascularization

10 % male; 64% NYHA functional class II and 36% NYHA functional class III/IV).

11 Association [NYHA] functional class II: 42%; NYHA functional class III: 28%; and NYHA functional clas

12 ry of heart failure (odds ratio [OR], 15.5), NYHA functional class > or =2 (OR, 5.4), and decreased s

13 baseline (median age 59 years; 71% male; 64% NYHA functional class II and 36% NYHA functional class I

14 nts experienced greater improvement in 6MHW, NYHA functional class, and QoL at six months compared to

15 (55% idiopathic PAH, 45% associated PAH, 94% NYHA class III, and mean baseline 6-MWD of 335 m) were r

16 After ablation, NYHA functional class (3 to 2.5; p < 0.05) and LVOT grad

17 t main coronary artery disease, and advanced NYHA heart failure class among VA patients undergoing CA

18 dysfunction were more pronounced in advanced NYHA classes (early mitral inflow velocity/early diastol

19 Those in more advanced NYHA functional classes (III and IV; n = 136) were older

20 were independently associated with advanced NYHA class.

21 ctive of increased operative risk to be age, NYHA functional class, concomitant procedures, and previ

22 Among patients with HCM, age, NYHA functional class, family history of sudden death (F

23 opensity score for receiving treatment, age, NYHA functional class, and ejection fraction.

24 h outcomes being significantly higher in all NYHA classes.

25 e devices should be considered in ambulatory NYHA class IV HF patients similar to those enrolled in C

26 uency ablation can be safely performed among NYHA IV patients.

27 By multivariate Cox analysis, NYHA functional class was independently associated with

28 Following Cox regression analysis, NYHA functional class (III vs. II; p < 0.05) remained th

29 cant differences between NYHA IV (n=111) and NYHA II and III (n=1254) NYHA IV had lower left ventricu

30 VR]versus 1.4+/-0.7 [with PVR], P=0.14), and NYHA class were similar in the 2 groups.

31 II: 42%; NYHA functional class III: 28%; and NYHA functional class IV: 4%).

32 central vs. 91.7% noncentral, p = 0.679; and NYHA functional class >II, 21.1% vs. 0%, p = 0.128) did

33 th (MR </=2, 96.0% vs. 96.6%, p = 0.866, and NYHA functional class </=II, 81.6% vs. 90.0%, p = 0.335)

34 so influenced the by the duration of CPB and NYHA III/IV; the impact of these risk factors varied wit

35 gnificantly improved 6-min walk distance and NYHA class at 12 weeks.

36 th severe systolic HF on the basis of EF and NYHA symptom class was assessed (receiver operating char

37 duration, treatment, dose, control, EF, and NYHA classification were extracted by using a standardiz

38 tion, include baseline ejection fraction and NYHA functional class, the number of septal arteries inj

39 , V(E)/V(CO2) slope), ejection fraction, and NYHA functional class (P<0.0001).

40 ved exercise tolerance, quality of life, and NYHA functional classification without an accompanying i

41 METHODS AND NYHA II-IV patients undergoing VT radiofrequency ablatio

42 RS duration of 120 milliseconds or more, and NYHA class II symptoms, CRT-D appears to be economically

43 e H/M, LVEF, B-type natriuretic peptide, and NYHA functional class.

44 r ejection fraction, the severity of PHT and NYHA functional class.

45 All patients are fully saturated and NYHA functional class I at latest clinic visit (0.3 to 8

46 A total of 224 patients with T2DM and NYHA functional class I to II CHF with LVEF < or =45% we

47 ersely affect LVEF in patients with T2DM and NYHA functional class I to II CHF.

48 ion fraction percent <40%) was classified as NYHA functional class I through IV when the AVP level wa

49 gned to a poorer New York Heart Association (NYHA) class (77.6% versus 66.0% in NYHA III/IV, respecti

50 ease were higher New York Heart Association (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versu

51 New York Heart Association (NYHA) class and echocardiography were assessed before an

52 odel showed that New York Heart Association (NYHA) class at baseline and follow-up predicted HFH (haz

53 patients were in New York Heart Association (NYHA) class I or II at 1 year.

54 nds or more, and New York Heart Association (NYHA) class I or II symptoms.

55 ntricular block; New York Heart Association (NYHA) class I, II, or III heart failure; and a left vent

56 21 patients with New York Heart Association (NYHA) class II or III CHF and a left ventricular ejectio

57 New York Heart Association (NYHA) class II through IV CHF patients with an LVEF of <

58 age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular

59 heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to rec

60 in patients with New York Heart Association (NYHA) class II-III heart failure, left ventricular eject

61 ication included New York Heart Association (NYHA) class III and IV heart failure, smoking, chronic o

62 in patients with New York Heart Association (NYHA) class III and IV HF.

63 in patients with New York Heart Association (NYHA) class III and IV HF.

64 /=18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced eject

65 articipants with New York Heart Association (NYHA) Class III heart failure symptoms and a previous ad

66 Patients with New York Heart Association (NYHA) class III heart failure, irrespective of the left

67 23 patients were New York Heart Association (NYHA) class III or IV at baseline.

68 2), preoperative New York Heart Association (NYHA) class III or IV heart failure status (14.3% vs 34.

69 white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunctio

70 to patients with New York Heart Association (NYHA) class III/IV symptoms (profile B: HR 2.23, p = 0.0

71 reinfarction, or New York Heart Association (NYHA) class IV heart failure.

72 e 51.3 years) in New York Heart Association (NYHA) class IV.

73 catheterization, New York Heart Association (NYHA) class, and cardiopulmonary exercise testing.

74 min walk (6 MW), New York Heart Association (NYHA) class, quality of life (QOL), and echocardiographi

75 rsus HT for each New York Heart Association (NYHA) class.

76 plasma UTN with New York Heart Association (NYHA) class.

77 ,010 patients in New York Heart Association (NYHA) classification II to IV heart failure taking angio

78 testing (pkVO2), New York Heart Association (NYHA) classification, and use of angiotensin-converting

79 Life Quality and New York Heart Association (NYHA) congestive heart failure functional class.

80 s was defined as New York Heart Association (NYHA) functional class > or =III.

81 15 patients with New York Heart Association (NYHA) functional class >/=II and moderate or greater fun

82 with symptomatic New York Heart Association (NYHA) functional class >/=II heart failure due to AL amy

83 0.9 to -0.2) for New York Heart Association (NYHA) functional class (p = 0.007), and 1.7 (0.7 to 2.6)

84 duration of AF, New York Heart Association (NYHA) functional class 1 or 2, smaller left atrial size,

85 associated with New York Heart Association (NYHA) Functional class and the composite outcome (all-ca

86 associated with New York Heart Association (NYHA) functional class and to analyze functional class i

87 LVEF and a poor New York Heart Association (NYHA) functional class are not usually referred for tran

88 rocedural MR and New York Heart Association (NYHA) functional class at 1 month (MR </=2, 96.0% vs. 96

89 on and duration, New York Heart Association (NYHA) functional class at 30 days, and 6-month mortality

90 patients were in New York Heart Association (NYHA) functional class I and 31% were in NYHA functional

91 RS interval, and New York Heart Association (NYHA) functional class I to II heart failure (HF).

92 Stable New York Heart Association (NYHA) functional class II and III systolic HF patients (

93 ion (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerul

94 ad severe TR and New York Heart Association (NYHA) functional class II to IV (mean age 76 +/- 13 year

95 in patients with New York Heart Association (NYHA) functional class II-IV chronic heart failure, left

96 61 subjects with New York Heart Association (NYHA) functional class II/III HF and left ventricular ej

97 AH patients with New York Heart Association (NYHA) functional class III (98%) or IV symptoms and a 6-

98 in patients with New York Heart Association (NYHA) functional class III or IV HF and a prolonged QRS.

99 perceived to be New York Heart Association (NYHA) functional class III or IV.

100 ts (79%) were in New York Heart Association (NYHA) functional class III or IV.

101 62 patients with New York Heart Association (NYHA) functional class III to IV HF and ejection fractio

102 ) for developing New York Heart Association (NYHA) functional class III to IV symptoms compared to no

103 re (MERIT-HF) in New York Heart Association (NYHA) functional class III/IV with left ventricular ejec

104 New York Heart Association (NYHA) functional class improved in the active treatment

105 The New York Heart Association (NYHA) functional class was obtained before the procedure

106 erity of MR, and New York Heart Association (NYHA) functional class were compared.

107 l/m(2), advanced New York Heart Association (NYHA) functional class, and age >or=75 years as risk fac

108 The New York Heart Association (NYHA) functional class, angina class, exercise duration,

109 Karnofsky index, New York Heart Association (NYHA) functional class, diastolic blood pressure, estima

110 6-MWD), modified New York Heart Association (NYHA) functional class, hemodynamic parameters, and time

111 re: age, gender, New York Heart Association (NYHA) functional class, left ventricular outflow tract (

112 plications were: New York Heart Association (NYHA) functional class, presence of shock, sinus tachyca

113 tolic volume, or New York Heart Association (NYHA) functional class, yielding hazard ratios between 1

114 by at least one New York Heart Association (NYHA) functional class.

115 ion, assessed by New York Heart Association (NYHA) functional class: I, 136+/-159 pg/mL; II, 338+/-43

116 failure are the New York Heart Association (NYHA) functional classification and the American Heart A

117 raction (EF) and New York Heart Association (NYHA) functional classification in patients with CHF.

118 ), and change in New York Heart Association (NYHA) functional classification.

119 imate of current New York Heart Association (NYHA) functional status was class 1 in 76%, class 2 in 2

120 n, in particular New York Heart Association (NYHA) I-II.

121 ge measurements, New York Heart Association (NYHA) symptom class, and resting pulmonary hemodynamics

122 s In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenon

123 ts (>/=60 years; New York Heart Association [NYHA] class II-IV, ischemic systolic HF) randomly assign

124 an American, 42% New York Heart Association [NYHA] class III or IV).

125 severe symptoms (New York Heart Association [NYHA] class III-IV), but there was no relationship with

126 cardiomyopathy (New York Heart Association [NYHA] functional class I or II) or nonischemic cardiomyo

127 t failure (CHF) (New York Heart Association [NYHA] functional class I to II).

128 echocardiogram (New York Heart Association [NYHA] functional class II: 42%; NYHA functional class II

129 rove Outcomes in New York Heart Association [NYHA] Functional Class III Heart Failure Patients) trial

130 rove Outcomes in New York Heart Association [NYHA] Functional Class III Heart Failure Patients).

131 ith advanced HF (New York Heart Association [NYHA] functional class III or IV and left ventricular ej

132 ion < or = 0.35, New York Heart Association [NYHA] functional class III or IV), prior AV junction abl

133 e heart failure (New York Heart Association [NYHA] functional class III or IV).

134 severe dyspnea (New York Heart Association [NYHA] functional class III or IV: 78%) and/or severe ang

135 ive HF patients (New York Heart Association [NYHA] functional class III to IV) were randomized to rec

136 nctional status (New York Heart Association [NYHA] functional class, 6-min walk distance, patient act

137 F hospitalization with CRT for asymptomatic (NYHA functional class I) patients, risks versus benefits

138 In asymptomatic (NYHA functional class I) patients, HF hospitalization ri

139 , baseline RVSP, together with age, baseline NYHA functional class, pre-operative AF, coronary artery

140 At baseline, NYHA class, LV EF, age, and use of cardiovascular drugs

141 he lower Hb quartiles were more likely to be NYHA functional class IV (p < 0.0001) and have lower pea

142 ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a high

143 There were significant differences between NYHA IV (n=111) and NYHA II and III (n=1254) NYHA IV had

144 omized patients with atrioventricular block, NYHA symptom class I to III heart failure, and left vent

145 T recurrence, and mortality were analyzed by NYHA IV status using Kaplan-Meier analysis and Cox propo

146 lass I or II) or nonischemic cardiomyopathy (NYHA functional class II only), sinus rhythm, an ejectio

147 no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.

148 fter ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).

149 rols (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well a

150 In patients with severe chronic NYHA class III to IV heart failure, the change in ST2 le

151 New York Heart Association functional class (NYHA-FC) and Canadian Cardiovascular Society Angina Clas

152 her New York Heart Association (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versus III; P=0.19

153 o-Sc >8, age, prior surgical commissurotomy, NYHA functional class IV, pre-PMV mitral regurgitation >

154 and heart failure patients of corresponding NYHA class (P=NS for each NYHA class).

155 During CRT, NYHA functional class decreased, LV dimensions normalize

156 nd AF, parameters of clinical deterioration (NYHA/WHO functional class, 6-minute walk distance, NT-pr

157 CG, body mass index, hypertension, diabetes, NYHA functional class, ejection fraction, left atrial ap

158 rovement in 6-min hall walk (6MHW) distance, NYHA functional class, and quality of life (QoL) over co

159 s of corresponding NYHA class (P=NS for each NYHA class).

160 At follow-up, 98% of patients were either NYHA class I or II and 87% were in normal sinus rhythm.

161 irrespective of age, gender, race, etiology, NYHA classification, and co-treatment therapy.

162 were required to have chronic heart failure (NYHA II-IV), previous admission for a cardiovascular rea

163 rial fibrillation, congestive heart failure (NYHA II/III), stable coronary artery disease, diabetes t

164 s III/IV and HR, 2.17; 95% CI, 1.54-3.04 for NYHA class II versus class I); other predictors were hea

165 95% confidence interval [CI], 2.74-5.79 for NYHA class III/IV and HR, 2.17; 95% CI, 1.54-3.04 for NY

166 nts (HR=3.20, 95% CI=1.75-5.88) adjusted for NYHA class and other risk factors.

167 ting for left ventricular ejection fraction, NYHA class, age, body mass index, diabetes mellitus, sex

168 It correlates with ventricular function, NYHA classification, and prognosis.

169 infarction (irrespective of their functional NYHA class) and patients within NYHA class II.

170 All had NYHA functional class III heart failure or greater on pr

171 Most patients had NYHA functional class IV symptoms at baseline.

172 ated activation of p70S6K, PKC-betaII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound

173 ell as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).

174 thy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patie

175 igher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.

176 Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylat

177 A subgroup of patients with advanced HF (NYHA class III/IV) consistently demonstrated improvement

178 ng sustainable exercise capacity) and higher NYHA class.

179 significant differences, even in the higher NYHA class groups.

180 Importantly, NYHA IV patients without recurrent VT had similar surviv

181 e LVOT obstruction and significantly improve NYHA functional class in patients with HOCM.

182 patients (compared with 9 placebo) improved NYHA functional classification by at least one class (p

183 Although DM was associated with improved NYHA class, 6-minute walk test results did not improve.

184 In NYHA functional class III to IV and age groups </=65 yea

185 ociation (NYHA) class (77.6% versus 66.0% in NYHA III/IV, respectively; P=0.01), and more demonstrate

186 t (p < 0.01) occurred after ablation (~5% in NYHA functional classes III and IV, and 8 patients in Ca

187 plant, and the remaining patients are all in NYHA class 1.

188 The other two patients are in NYHA class 1, 642 and 889 days after implant.

189 Changes in NYHA class (p = 0.10) and QOL (p = 0.40) were not statis

190 luated using the 6-min walk test, changes in NYHA functional class, cardiac function, and quality of

191 es showed a clinically important decrease in NYHA class at 6 to 11 months (range, -0.8 to -2.1 classe

192 sponse to CRT with LVEF >45% and decrease in NYHA functional class at 1 year.

193 tly associated with mortality, especially in NYHA IV patients.

194 all-cause mortality and hospitalizations in NYHA class IV patients, with a trend for improved mortal

195 0.8% +/- 6.1%; P < 0.001) and improvement in NYHA class (-0.9 +/- 0.7 vs. -0.5 +/- 0.8; P = 0.02).

196 ricular pacing showed greater improvement in NYHA functional class at 12 months, with 19% improved, 6

197 No additional improvement in NYHA functional class or QoL was seen compared to the si

198 Although improvements in NYHA class were more likely with DM (P<0.001), 6-minute

199 also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of hea

200 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven

201 patients but 1 demonstrated improvements in NYHA functional status (to class II) with pronounced red

202 es HF hospitalizations, and improves LVEF in NYHA functional class I/II HF patients.

203 onitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial w

204 onitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients [CHAMPION]; NCT005

205 onitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients trial) analyzed PA

206 Patients in NYHA class I increased from 12 (23%) to 42 (79%) at 12 m

207 th a similar percentage of those patients in NYHA class I/II (73% tilarginine vs 75% placebo; P = .27

208 Noticeably, the proportion of patients in NYHA functional class III at the end of follow-up was 13

209 0.62; P=0.040), which was more pronounced in NYHA classes III and IV.

210 In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion

211 n fraction < or = 35%, particularly those in NYHA class II, as long as the benefits of ICD therapy ob

212 Elimination of recurrent VT in NYHA IV patients may reduce mortality to a level compara

213 of these initial feasibility studies were in NYHA class 4.

214 patients was 25 percent; 70 percent were in NYHA class II, and 30 percent were in class III CHF.

215 Of the patients, 88 were in NYHA functional class I or II and 12 were in NYHA functi

216 ne-year survivors of the SHOCK trial were in NYHA functional class I or II.

217 on (NYHA) functional class I and 31% were in NYHA functional class II; and 18% had atrial fibrillatio

218 NYHA functional class I or II and 12 were in NYHA functional class III.

219 nuloplasty and 25% having CABG alone were in NYHA functional class III/IV.

220 mortality by multivariate analysis included NYHA functional class (III vs. II), estimated glomerular

221 Younger age, increased NYHA class, lower ejection fraction, and less depression

222 ndergoing follow-up CMR, we found an initial NYHA functional class >I as the best independent predict

223 rinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687).

224 d among New York Heart Association class IV (NYHA IV) heart failure patients.

225 ssociated with shorter duration of AF, lower NYHA class, smaller left atrial size, and absence of lef

226 SV]) and quality-of-life (QoL) measurements (NYHA functional class, Minnesota Living with Heart Failu

227 ith PPH (58 female, age 46+/-2 years, median NYHA class III) between 1996 and 2001 who were followed

228 g characteristic curve area for diagnosis of NYHA class I HF with UTN was better than that with N-BNP

229 that these relationships were independent of NYHA class, peak V(O2), and V(E)/V(CO2) slope.

230 lications from thrombolysis, irrespective of NYHA functional class.

231 Management of NYHA Class III heart failure based on home transmission

232 Time to first occurrence of NYHA functional class progression, potentially life-thre

233 We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Med

234 Rates of NYHA class IV heart failure (4.4% vs. 4.5%) and death (9

235 ated with subsequent mortality regardless of NYHA status.

236 )(0) supplementation that reported the EF or NYHA functional class as a primary outcome.

237 ls are elevated irrespective of age, sex, or NYHA class.

238 01) compared with less symptomatic patients (NYHA class II; n = 57).

239 In nonanemic patients, NYHA functional class improved (p = 0.06).

240 vels <200 pg/ml (66% of which were perceived NYHA functional class III or IV).

241 variables-B-type natriuretic peptide, pkVO2, NYHA, and angiotensin-converting enzyme inhibitor/angiot

242 ge was 57+/-9 years, and median preoperative NYHA class was 3.

243 e to clinical worsening, Borg Dyspnea Score, NYHA functional class, 12-week trough 6MWD, 6-week peak

244 e to clinical worsening, Borg Dyspnea Score, NYHA functional class, and PAH signs and symptoms.

245 emale patients and in those with more severe NYHA class.

246 s associated with a worse symptomatic state (NYHA class, P<0.05), lower exercise tolerance (peak VO(2

247 monitoring on 104 patients with symptomatic NYHA II to IV heart failure (HFpEF, n=48, peak Vo2=13.9+

248 Of the remaining 498 symptomatic (NYHA functional class II-III) patients, 106 (21.3%) had

249 Among mildly symptomatic (NYHA functional class II) patients, CRT was associated w

250 atients with moderate-to-severe HF symptoms (NYHA class > 2), PEC time had good accuracy (AUC, 0.875

251 The NYHA functional class improved significantly in those wi

252 The NYHA functional class substantially improved in both gro

253 The NYHA functional classification improved 29% (p < 0.001).

254 The NYHA-FC worsened with time in both rate-control and rhyt

255 sidual confounding analyses and analyzed the NYHA I-II and III-IV subgroups separately.

256 he EF and -0.30 (95% CI: -0.66, 0.06) in the NYHA functional class.

257 In the NYHA I-II subgroup, after adjustment for propensity scor

258 VT, and 1-year mortality were higher in the NYHA IV group, in the context of greater baseline comorb

259 er the AHA/ACC heart failure staging nor the NYHA functional classification system identifies the var

260 ed widely in HF without consideration of the NYHA class and ejection fraction, and without optimizati

261 s of CHF, but they did vary according to the NYHA class.

262 significant improvement was noted, with the NYHA functional class decreasing to 1, exercise duration

263 placement had a similar improvement in their NYHA functional class, septal thickness reduction, LVOT

264 ay reduce mortality to a level comparable to NYHA II and III with arrhythmia recurrence.

265 40% and development of heart failure (HF) to NYHA functional class II to IV over several years; 4) ma

266 months and 79% (DT) at 24 months improved to NYHA functional class I or II.

267 lative risk, 1.6; P=0.02) and progression to NYHA class III or IV or death from heart failure or stro

268 The risk of progression to NYHA class III or IV or death specifically from heart fa

269 showed that BNP was independently related to NYHA class as well as age and left ventricular wall thic

270 went physical rehabilitation and returned to NYHA class I.

271 evels from the PRAISE-2 heart failure trial (NYHA functional class III-IV; end point, mortality or tr

272 eart Association (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versus III; P=0.19; NYHA I versu

273 tients alive 30 days after implantation were NYHA class I or II.

274 Preoperatively, 67% of patients were NYHA functional class III or IV and postoperatively, 85%

275 In patients </=80 years of age with NYHA functional class III to IV HF and ejection fraction

276 urrent VT had similar survival compared with NYHA II and III patients with recurrent VT (68% versus 7

277 ses identified 32 biomarkers correlated with NYHA class and 28 predicting outcomes.

278 n ATTR amyloidosis, survival correlated with NYHA functional class, diastolic blood pressure, and use

279 ith DCM, AVP levels correlated directly with NYHA functional class (r2=0.73, P<0.001).

280 d left ventricular systolic dysfunction with NYHA class I, II, or III heart failure.

281 Spironolactone interacted with NYHA (P<0.001).

282 cost-effectiveness of CRT-D in patients with NYHA class I symptoms remains uncertain.

283 Data on patients with NYHA class I symptoms were limited.

284 per QALY gained was $44 531 in patients with NYHA class II heart failure and $58 194 in those with cl

285 In patients with NYHA class II or III CHF and LVEF of 35 percent or less,

286 n plasma aldosterone levels in patients with NYHA class II through IV heart failure.

287 lar mortality and morbidity in patients with NYHA class II to IV heart failure.

288 OMPANION trial randomized 1520 patients with NYHA class III and IV HF to optimal medical therapy, CRT

289 duction in hospitalisation for patients with NYHA class III heart failure who were managed with a wir

290 dose trial of etanercept in 47 patients with NYHA class III to IV heart failure.

291 linical trials including 4,317 patients with NYHA functional class I/II HF was performed.

292 mortality (36%, p < 0.002) in patients with NYHA functional class III and IV heart failure and ventr

293 antagonism were studied in 17 patients with NYHA grade II through IV heart failure maintained on chr

294 myocardial infarction (n=919) and those with NYHA II heart failure (n=689)--IMT was associated with a

295 and characteristic and correlated well with NYHA class.

296 patients (age 71+/-12 years; 28% women) with NYHA I-IV and ejection fraction <40% who were registered

297 r functional NYHA class) and patients within NYHA class II.

298 ablation outcomes of those with and without NYHA IV in the International VT Ablation Center Collabor

299 Presence of AF was associated with worse NYHA-FC (p < 0.0001).

300 Presence of AF was associated with worse NYHA-FC.